{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:57:22Z","timestamp":1793739442304,"version":"4.6.1"},"reference-count":49,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Key R & D Program of Hubei Province","award":["2023BCB149"],"award-info":[{"award-number":["2023BCB149"]}]},{"name":"Key R & D Program of Hubei Province","award":["2025CCB003"],"award-info":[{"award-number":["2025CCB003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC","doi-asserted-by":"crossref","award":["82370770"],"award-info":[{"award-number":["82370770"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741278"],"award-info":[{"award-number":["2023M741278"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is a prevalent malignancy with limited treatment options for advanced stages. Oncolytic virotherapy represents a promising immunotherapeutic approach, but its efficacy and underlying mechanisms in PCa, particularly concerning immune checkpoint regulation, remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The antitumor effects of the oncolytic virus oncolytic herpes simplex virus type 2 (OH2) were evaluated in PCa cell lines and mouse models. Transcriptome sequencing, western blot, chromatin immunoprecipitation-sequencing-quantitative PCR, and flow cytometry were employed to investigate the mechanism of programmed death 1 ligand 1 (PD-L1) regulation. A targeted delivery system, reactive oxygen species (ROS)-responsive aptamer-conjugated anti-prostate-specific membrane antigen (PSMA) extracellular vesicles (RRA-AP-EVs), was engineered from anti-PSMA single chain variable fragment (scFv)-modified extracellular vesicles and an ROS-responsive PD-L1 blocking aptamer. OH2 was loaded via membrane extrusion, and the resulting OH2@RRA-AP-EVs were tested for targeting and therapeutic efficacy following intravenous administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OH2 effectively killed PCa cells but simultaneously activated the IKK\/I-\u03baB\u03b1\/p65 pathway, leading to PD-L1 upregulation and adaptive immune resistance. While combining OH2 with anti-PD-L1 improved outcomes, clinical translation was hindered by delivery challenges. The novel OH2@RRA-AP-EVs system demonstrated precise tumor targeting and ROS-triggered local PD-L1 blockade. Intravenous injection of OH2@RRA-AP-EVs showed superior tumor control (inhibiting tumor growth by 70% vs free OH2) and enhanced CD8+T\u2009cell infiltration and function compared with free OH2 (greater than twofold increase in intratumoral CD8+T\u2009cell infiltration along with over twofold upregulation of key effector molecules).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies a mechanism of OH2-induced PD-L1 expression in PCa and provides a versatile, targeted delivery platform that enables effective intravenous viro-immunotherapy, overcoming key translational barriers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013818","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:30:26Z","timestamp":1770049826000},"page":"e013818","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Oncolytic virus OH2 induces PD-L1 upregulation via NF-\u03baB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-2238","authenticated-orcid":false,"given":"Jin-Zhou","family":"Xu","sequence":"first","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"An","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Xuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"},{"name":"Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Science, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Han","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yu","family":"Xia","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Binhui Biopharmaceutical Co Ltd, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ci-Xiang","family":"Guo","sequence":"additional","affiliation":[{"name":"National \"111\" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hebei University of Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Binhui Biopharmaceutical Co Ltd, Wuhan, China"},{"name":"National \"111\" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hebei University of Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guan","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-1495","authenticated-orcid":false,"given":"Shao-Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-1122","authenticated-orcid":false,"given":"Qi-Dong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department and Institute of Urology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026062607451031000_14.2.e013818.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"2026062607451031000_14.2.e013818.2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.00000000 00001474"},{"key":"2026062607451031000_14.2.e013818.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02137-1","article-title":"Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"2026062607451031000_14.2.e013818.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0014-6"},{"key":"2026062607451031000_14.2.e013818.5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/hum.2018.170","article-title":"Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2","volume":"30","author":"Wang","year":"2019","journal-title":"Hum Gene Ther"},{"key":"2026062607451031000_14.2.e013818.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062607451031000_14.2.e013818.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009443","article-title":"Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling","volume":"12","author":"Armstrong","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026062607451031000_14.2.e013818.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00763-8"},{"key":"2026062607451031000_14.2.e013818.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.01.002"},{"key":"2026062607451031000_14.2.e013818.10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12916-022-02574-z","article-title":"SIRP\u03b1 antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment","volume":"20","author":"Kong","year":"2022","journal-title":"BMC Med"},{"key":"2026062607451031000_14.2.e013818.11","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms2282","article-title":"Delivery of chemotherapeutic drugs in tumour cell-derived microparticles","volume":"3","author":"Tang","year":"2012","journal-title":"Nat Commun"},{"key":"2026062607451031000_14.2.e013818.12","doi-asserted-by":"crossref","first-page":"145236","DOI":"10.1016\/j.ijbiomac.2025.145236","article-title":"Targeted delivery of doxorubicin toward 4 T1 cells via in situ binding between maleimide functionalized AS1411 - NH2 aptamer and endogenous albumin","volume":"318","author":"Hamooni","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"2026062607451031000_14.2.e013818.13","doi-asserted-by":"crossref","first-page":"45455","DOI":"10.1021\/acsami.9b16637","article-title":"Aptamer-Based Erythrocyte-Derived Mimic Vesicles Loaded with siRNA and Doxorubicin for the Targeted Treatment of Multidrug-Resistant Tumors","volume":"11","author":"Wang","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"2026062607451031000_14.2.e013818.14","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.102","article-title":"A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects","volume":"5","author":"Lai","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026062607451031000_14.2.e013818.15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2025.01.079","article-title":"A novel prostate cancer-specific fluorescent probe based on extracellular vesicles targeting STEAP1 applied in fluorescence guided surgery","volume":"380","author":"Sun","year":"2025","journal-title":"J Control Release"},{"key":"2026062607451031000_14.2.e013818.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38679-z","article-title":"Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy","volume":"14","author":"Ban","year":"2023","journal-title":"Nat Commun"},{"key":"2026062607451031000_14.2.e013818.17","doi-asserted-by":"crossref","first-page":"216834","DOI":"10.1016\/j.canlet.2024.216834","article-title":"OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses","volume":"589","author":"Zheng","year":"2024","journal-title":"Cancer Lett"},{"key":"2026062607451031000_14.2.e013818.18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41417-021-00350-4","article-title":"CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"2026062607451031000_14.2.e013818.19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw855"},{"key":"2026062607451031000_14.2.e013818.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.08.002"},{"key":"2026062607451031000_14.2.e013818.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010662","article-title":"Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia\/Ib trial results and biomarker insights","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026062607451031000_14.2.e013818.22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment","volume":"11","author":"Ma","year":"2025","journal-title":"Trends Cancer"},{"key":"2026062607451031000_14.2.e013818.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010543","article-title":"Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1\/2 trial","volume":"13","author":"Tan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026062607451031000_14.2.e013818.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09915","article-title":"Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma","volume":"8","author":"de Graaf","year":"2022","journal-title":"Heliyon"},{"key":"2026062607451031000_14.2.e013818.25","doi-asserted-by":"crossref","unstructured":"Yang F , Shay C , Abousaud M , et al . Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res 2023;42. doi:10.1186\/s13046-022-02568-y","DOI":"10.1186\/s13046-022-02568-y"},{"key":"2026062607451031000_14.2.e013818.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z"},{"key":"2026062607451031000_14.2.e013818.27","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202306389","article-title":"A Factor\u2010Free Hydrogel with ROS Scavenging and Responsive Degradation for Enhanced Diabetic Bone Healing","volume":"20","author":"Zhang","year":"2024","journal-title":"Small"},{"key":"2026062607451031000_14.2.e013818.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w"},{"key":"2026062607451031000_14.2.e013818.29","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1021\/acs.nanolett.2c03227","article-title":"ROS-Responsive Nanocomplex of aPD-L1 and Cabazitaxel Improves Intratumor Delivery and Potentiates Radiation-Mediated Antitumor Immunity","volume":"22","author":"Wang","year":"2022","journal-title":"Nano Lett"},{"key":"2026062607451031000_14.2.e013818.30","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1670893","article-title":"Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity","volume":"8","author":"Hong","year":"2019","journal-title":"J Extracell Vesicles"},{"key":"2026062607451031000_14.2.e013818.31","first-page":"527","article-title":"Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer","volume":"25","author":"Zhou","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"2026062607451031000_14.2.e013818.32","doi-asserted-by":"crossref","first-page":"114827","DOI":"10.1016\/j.addr.2023.114827","article-title":"Myeloid cell-mediated drug delivery: From nanomedicine to cell therapy","volume":"197","author":"Zhang","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"2026062607451031000_14.2.e013818.33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.02.025","article-title":"Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy","volume":"89","author":"Ran","year":"2016","journal-title":"Biomaterials"},{"key":"2026062607451031000_14.2.e013818.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00571-6"},{"key":"2026062607451031000_14.2.e013818.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.12.010"},{"key":"2026062607451031000_14.2.e013818.36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature New Biol"},{"key":"2026062607451031000_14.2.e013818.37","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12473","article-title":"A new subtype of artificial cell-derived vesicles from dental pulp stem cells with the bioequivalence and higher acquisition efficiency compared to extracellular vesicles","volume":"13","author":"Duan","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"2026062607451031000_14.2.e013818.38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13244-020-00926-y","article-title":"Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET\/MRI imaging in patients with prostate cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Insights Imaging"},{"key":"2026062607451031000_14.2.e013818.39","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41391-024-00930-z","article-title":"Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer","volume":"28","author":"Incesu","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026062607451031000_14.2.e013818.40","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1038\/s41467-024-52500-5","article-title":"Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"2026062607451031000_14.2.e013818.41","doi-asserted-by":"crossref","first-page":"1200466","DOI":"10.3389\/fcell.2023.1200466","article-title":"The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer","volume":"11","author":"Xie","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2026062607451031000_14.2.e013818.42","doi-asserted-by":"crossref","first-page":"101335","DOI":"10.1016\/j.mam.2024.101335","article-title":"The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy","volume":"101","author":"Xie","year":"2025","journal-title":"Mol Aspects Med"},{"key":"2026062607451031000_14.2.e013818.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41396-023-01483-0"},{"key":"2026062607451031000_14.2.e013818.44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026062607451031000_14.2.e013818.45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.21147\/j.issn.1000-9604.2024.03.07","article-title":"Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer","volume":"36","author":"Li","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"2026062607451031000_14.2.e013818.46","doi-asserted-by":"crossref","first-page":"145125","DOI":"10.1016\/j.ijbiomac.2025.145125","article-title":"AS1411 aptamer based nanomaterials: A novel approach for breast cancer therapy","volume":"318","author":"Verma","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"2026062607451031000_14.2.e013818.47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"2026062607451031000_14.2.e013818.48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.21147\/j.issn.1000-9604.2025.05.07","article-title":"Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy","volume":"37","author":"Huang","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"2026062607451031000_14.2.e013818.49","unstructured":"Data from treatment of prostate cancer with oncolytic virus OH2 (RNA-seq). NCBI SRA; 2025. Available: https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA1264063"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:28Z","timestamp":1782485128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013818"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013818","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}